Annual report pursuant to Section 13 and 15(d)

Composition of Certain Financial Statement Captions (Details 1)

v2.4.0.8
Composition of Certain Financial Statement Captions (Details 1) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Technology [Member]
Dec. 31, 2013
Customer relationships [Member]
Dec. 31, 2013
Product registrations [Member]
Dec. 31, 2013
Covenants Not to Compete [Member]
Dec. 31, 2013
Tradename [Member]
Dec. 31, 2013
Other [Member]
Dec. 31, 2013
OPKO Chile [Member]
Dec. 31, 2013
OPKO Chile [Member]
Customer relationships [Member]
Dec. 31, 2013
OPKO Chile [Member]
Product registrations [Member]
Dec. 31, 2013
OPKO Chile [Member]
Tradename [Member]
Dec. 31, 2013
Exakta OPKO [Member]
Dec. 31, 2013
Exakta OPKO [Member]
Customer relationships [Member]
Dec. 31, 2013
Exakta OPKO [Member]
Product registrations [Member]
Dec. 31, 2013
Exakta OPKO [Member]
Covenants Not to Compete [Member]
Dec. 31, 2013
Exakta OPKO [Member]
Tradename [Member]
Dec. 31, 2013
CURNA [Member]
Dec. 31, 2013
CURNA [Member]
In-process research research and development [Member]
Dec. 31, 2013
CURNA [Member]
Other [Member]
Dec. 31, 2013
OPKO Diagnostics [Member]
Dec. 31, 2013
OPKO Diagnostics [Member]
Technology [Member]
Dec. 31, 2013
FineTech [Member]
Dec. 31, 2013
FineTech [Member]
Technology [Member]
Dec. 31, 2013
FineTech [Member]
Customer relationships [Member]
Dec. 31, 2013
FineTech [Member]
Covenants Not to Compete [Member]
Dec. 31, 2013
FineTech [Member]
Tradename [Member]
Dec. 31, 2013
Farmadiet [Member]
Dec. 31, 2013
Farmadiet [Member]
Technology [Member]
Dec. 31, 2013
Farmadiet [Member]
In-process research research and development [Member]
Dec. 31, 2013
Farmadiet [Member]
Customer relationships [Member]
Dec. 31, 2013
Farmadiet [Member]
Product registrations [Member]
Dec. 31, 2013
Farmadiet [Member]
Covenants Not to Compete [Member]
Dec. 31, 2013
Farmadiet [Member]
Tradename [Member]
Dec. 31, 2013
OURLab [Member]
Dec. 31, 2013
OURLab [Member]
Technology [Member]
Dec. 31, 2013
OURLab [Member]
Customer relationships [Member]
Dec. 31, 2013
OURLab [Member]
Covenants Not to Compete [Member]
Dec. 31, 2013
OURLab [Member]
Tradename [Member]
Dec. 31, 2013
OURLab [Member]
Other [Member]
Dec. 31, 2013
SciGen [Member]
Dec. 31, 2013
SciGen [Member]
Technology [Member]
Dec. 31, 2013
SciGen [Member]
Customer relationships [Member]
Dec. 31, 2013
OPKO Brazil [Member]
Dec. 31, 2013
OPKO Brazil [Member]
Other [Member]
Dec. 31, 2013
Cytochroma [Member]
Dec. 31, 2013
Cytochroma [Member]
In-process research research and development [Member]
Dec. 31, 2013
Cytochroma [Member]
Other [Member]
Dec. 31, 2013
PROLOR [Member]
Aug. 29, 2013
PROLOR [Member]
Dec. 31, 2013
PROLOR [Member]
In-process research research and development [Member]
Fair values assigned to major intangible asset classes upon each acquisition                                                                                                        
Total identified intangible assets                   $ 10,806 [1] $ 3,945 [1] $ 5,829 [1] $ 1,032 [1] $ 345 $ 121 $ 77 $ 70 $ 77 $ 10,290 $ 10,000 $ 290 $ 44,400 $ 44,400 $ 18,800 $ 2,700 $ 14,200 $ 1,500 $ 400 $ 8,378 $ 3,017 $ 1,459 $ 436 $ 2,930 $ 187 $ 349 $ 14,030 $ 1,370 $ 3,860 $ 6,900 $ 1,830 $ 70 $ 1,130 $ 1,090 $ 40 $ 686 $ 686 $ 191,740 $ 191,530 $ 210 $ 590,200   $ 590,200
Goodwill $ 226,373 [2] $ 80,450 [2] $ 39,815             $ 5,441 [1]       $ 21         $ 4,827     $ 17,977   $ 11,623         $ 8,062             $ 29,629           $ 760         $ 2,411     $ 139,784 $ 139,784  
Weighted average amortization period       9 years 6 years 9 years 5 years 4 years 4 years                                                                                      
[1] Current assets include cash of $0.4 million and $20.5 million related to the Cytochroma and PROLOR acquisitions, respectively
[2] As of December 31, 2013 and 2012, total assets include $6.7 million and $5.6 million, respectively, and total liabilities include $10.4 million and $5.5 million, respectively related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and the holders of SciVac’s consolidated liabilities have no recourse against us. Refer to Note 3.